Viral delivery of opsins to peripheral nociceptors allows optogenetic stimulation and inhibition of pain in non-transgenic freely moving mice. Primary nociceptors are the first neurons involved in the complex processing system that regulates normal and pathological pain1. Because of constraints on pharmacological and electrical stimulation, noninvasive excitation and inhibition of these neurons in freely moving nontransgenic animals has not been possible. Here we use an optogenetic2 strategy to bidirectionally control nociceptors of nontransgenic mice. Intrasciatic nerve injection of adeno-associated viruses encoding an excitatory opsin enabled light-inducible stimulation of acute pain, place aversion and optogenetically mediated reductions in withdrawal thresholds to mechanical and thermal stimuli. In contrast, viral delivery of an inhibitory opsin enabled light-inducible inhibition of acute pain perception, and reversed mechanical allodynia and thermal hyperalgesia in a model of neuropathic pain. Light was delivered transdermally, allowing these behaviors to be induced in freely moving animals. This approach may have utility in basic and translational pain research, and enable rapid drug screening and testing of newly engineered opsins.
Optogenetic control of the peripheral nervous system (PNS) would enable novel studies of motor control, somatosensory transduction, and pain processing. Such control requires the development of methods to deliver opsins and light to targeted sub-populations of neurons within peripheral nerves. We report here methods to deliver opsins and light to targeted peripheral neurons and robust optogenetic modulation of motor neuron activity in freely moving, non-transgenic mammals. We show that intramuscular injection of adeno-associated virus serotype 6 enables expression of channelrhodopsin (ChR2) in motor neurons innervating the injected muscle. Illumination of nerves containing mixed populations of axons from these targeted neurons and from neurons innervating other muscles produces ChR2-mediated optogenetic activation restricted to the injected muscle. We demonstrate that an implanted optical nerve cuff is well-tolerated, delivers light to the sciatic nerve, and optically stimulates muscle in freely moving rats. These methods can be broadly applied to study PNS disorders and lay the groundwork for future therapeutic application of optogenetics.
1 November 2010 in Journal of Neuroscience Methods
Motor evoked potential (MEP) signals serve as an objective measure of the functional integrity of motor pathways in the spinal cord. Hence, they provide a reliable assessment of the extent of spinal cord injury (SCI). There are two methods currently being used for serial MEP recordings in rats: a low-frequency and a high-frequency method. In this paper, we compared the two methods and determined the better method for MEP recordings. We also compared the effect of two anesthetic agents- inhalational isoflurane and intraperitoneal ketamine - on the MEP signals. We found that under ketamine anesthesia, low-frequency stimulation led to more consistent results, while high-frequency stimulation required greater stimulation intensity and was prone to unwanted side-effects including excessive head twitches. We further found that isoflurane anesthesia severely depressed the MEP response for both low-frequency and high-frequency stimulation which rendered the resulting signal unusable.
Applying tools from optogenetics with ideas from regenerative medicine may herald a new era of translational optogenetics. [Also see Report by Bryson et al. ]